Skip to content
ORPHELIA Pharma
  • About us
  • Therapeutic Areas
    • Pipeline
    • Neurology
    • Oncology
  • Partners
  • News
  • Contact
×
  • About us
  • Therapeutic Areas
    • Pipeline
    • Neurology
    • Oncology
  • Partners
  • News
  • Contact
ORPHELIA Pharma

    Hear from us

    12 March 2025

    Orphelia Pharma provides update on KIZFIZO® regulatory submission with the European Medicines Agency

    Read More >
    18 November 2024

    Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency

    Read More >
    11 June 2024

    ORPHELIA Pharma to collaborate with Oscar Lambret clinical center to study KIZFIZO®, the first pediatric drinkable formulation of temozolomide, for the treatment of refractory or relapsed nephroblastoma (Wilms tumor)

    Read More >
    22 May 2024

    ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®

    Read More >
    18 April 2024

    Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin

    Read More >
    5 March 2024

    International Drug Repurposing Conference 2024, 6-7th March 2024, Barcelona

    Read More >

    ORPHELIA Pharma
    85 boulevard Saint Michel
    75005 Paris – France
    Tel : +33 1 42 77 08 18
    Contact us

    • Politique de confidentialité
    • Data privacy policy
    ×
    • Politique de confidentialité
    • Data privacy policy